Leqvio (Inclisiran) Side Effects, Withdrawal, and Discontinuation Syndrome

What Is Inclisiran and How Does the Dosing Schedule Work?

Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 messenger RNA inside hepatocytes, reducing PCSK9 protein synthesis and thereby increasing LDL receptor recycling on the liver surface. A single 284 mg subcutaneous injection on Day 1, a second on Day 90, and then one injection every six months produces a sustained ~50% LDL-C reduction at trough. That twice-yearly schedule distinguishes it from monoclonal antibody PCSK9 inhibitors dosed every two to four weeks.

Mechanism Relevance to Safety

Because inclisiran acts intracellularly via RNA interference rather than blocking circulating protein, it has no receptor-binding off-target activity in peripheral tissue. This narrows the plausible adverse-event pathways compared with small-molecule drugs and explains why most observed side effects cluster at the injection site rather than systemically.

The FDA approved inclisiran on December 22, 2021, under the brand name Leqvio for adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH), used alongside maximally tolerated statin therapy. [1]

Key Trial Overview

The ORION phase 3 program comprised three replicate double-blind, placebo-controlled trials: ORION-9 (HeFH), ORION-10 (ASCVD), and ORION-11 (ASCVD or ASCVD risk equivalents). Pooled enrollment across these three trials exceeded 3,500 patients, with follow-up to 18 months. [2] The safety database underpinning the FDA label draws primarily from this program, supplemented by ORION-1 (phase 2) and the long-term ORION-3 open-label extension.

Common Side Effects of Leqvio

The most frequently reported adverse events in key trials were injection-site reactions, occurring in approximately 8.2% of inclisiran-treated patients versus 1.8% in the placebo group. [2] Most reactions were mild or moderate in severity and did not lead to discontinuation.

Injection-Site Reactions

Specific injection-site reactions recorded in ORION-10 and ORION-11 include:

• Erythema (redness)
• Pain or tenderness
• Bruising (ecchymosis)
• Swelling or induration

In the pooled ORION-9, -10, -11 analysis published in the New England Journal of Medicine (N=3,655 patient-years of inclisiran exposure), no injection-site reaction was rated severe, and none progressed to tissue necrosis or abscess. [2] Reactions typically resolved within seven days without intervention.

Patients with prior statin-related muscle complaints do not appear to carry elevated injection-site risk. The mechanism is local inflammatory response to the lipid nanoparticle excipient rather than an immunoglobulin E-mediated allergic reaction.

Upper Respiratory Tract Infections

Nasopharyngitis and upper respiratory tract infections appeared numerically more common in the inclisiran arm (approximately 7.5% vs. 5.8% placebo) in ORION-10, though the difference did not reach statistical significance (P<0.05 threshold not met) and is consistent with background population rates. [3]

Arthralgia and Musculoskeletal Complaints

Arthralgia was reported in roughly 5.3% of inclisiran patients versus 4.6% on placebo across the pooled trials. This marginal difference is unlikely to be drug-related, given that the population already had high statin co-medication rates, and statins themselves carry a well-documented myalgia risk.

Laboratory Abnormalities

Transient mild elevations in serum creatinine (mean increase of 0.04 mg/dL from baseline at month 3) were observed in ORION-10. [3] The FDA label notes that this small change stabilized and was not associated with clinical renal events. Liver transaminases (ALT, AST) showed no clinically meaningful differences between inclisiran and placebo arms.

Serious and Rare Adverse Events

Serious adverse events (SAEs) occurred at rates that were statistically indistinguishable between inclisiran and placebo in all three key trials. [2] The FDA label's Table 1 lists SAE incidence of 7.5% for inclisiran versus 8.4% for placebo in the pooled population, meaning the drug did not add to serious event risk.

Cardiovascular Events During Trials

Because the ORION-9, -10, and -11 trials were not powered as cardiovascular outcome trials, they could not demonstrate superiority on MACE endpoints. The dedicated cardiovascular outcome trial, ORION-4, is ongoing at approximately 15,000 patients. Interim data available through the 2024 European Society of Cardiology meeting showed no safety signal driving excess cardiovascular events in the inclisiran arm. [4]

Hypersensitivity and Anaphylaxis

No cases of anaphylaxis were reported in the phase 3 program (N>3,500). The FDA label lists hypersensitivity reactions as a general warning class but acknowledges the absence of confirmed cases in clinical trials. Post-marketing pharmacovigilance through the FDA Adverse Event Reporting System (FAERS) has not generated a signal for anaphylaxis through the publicly available quarterly data extracts as of 2024. [5]

Liver Safety

Hepatic safety was prospectively monitored. In ORION-11 (N=1,617), ALT greater than three times the upper limit of normal occurred in 0.6% of inclisiran patients versus 0.7% placebo. [3] The Hy's Law signal was absent. Given that inclisiran silences PCSK9, and PCSK9 loss-of-function variants in humans are associated with modest steatohepatitis risk in long-term epidemiologic studies, extended liver safety monitoring beyond 18 months remains an area of active research interest. [6]

Neurocognitive Effects

Cognitive adverse events (memory impairment, confusion) were reported by 0.4% on inclisiran versus 0.3% on placebo in the pooled ORION analysis. This difference is not statistically significant. The question of whether any PCSK9 inhibitor affects brain cholesterol metabolism remains a topic of ongoing research, partly because PCSK9 is expressed in neurons, but inclisiran's large molecular size and siRNA cargo limit CNS penetration. [7]

Does Leqvio Cause a Withdrawal Syndrome When You Stop?

No. Inclisiran does not produce a pharmacologic withdrawal syndrome. There are no physical dependence pathways, no receptor upregulation, and no rebound hyper-reactivity analogous to beta-blocker or opioid withdrawal. Stopping inclisiran is metabolically uneventful in the short term.

LDL-C Rebound After Discontinuation

The clinically meaningful consequence of stopping inclisiran is the gradual return of LDL-C toward baseline. Because the drug suppresses PCSK9 mRNA rather than the protein directly, the effect persists as long as the silencing complex (RISC) remains active in hepatocytes. Pharmacokinetic modeling from ORION-3 extension data suggests that LDL-C begins rising approximately three to four months after a missed dose and returns to within 10% of pre-treatment baseline by approximately six to nine months post-last injection in most patients. [8]

This is not a rebound overshoot. LDL-C does not rise above pre-treatment values. The trajectory mirrors natural clearance of the hepatic RISC complex.

Clinical Implications of Stopping

The ORION-3 open-label extension enrolled patients originally from ORION-1 phase 2 and followed them for up to four years. Patients who re-initiated inclisiran after a gap achieved LDL-C reductions comparable to their initial response, indicating no tachyphylaxis (loss of drug effect over time) and no penalty for a treatment gap. [8]

For clinicians, this means:

• A patient who misses a scheduled injection does not need a loading dose; simply resume the every-six-month schedule.
• Patients planning elective surgery who are advised to hold the drug face no pharmacologic hazard from the pause itself, only the cardiovascular risk from rising LDL-C.
• Pregnancy discovery after a dose should trigger drug discontinuation. The returning LDL-C trajectory is predictable and manageable with diet and, if necessary, bile acid sequestrants (the only lipid-lowering class without pregnancy signal).

What Prescribers Should Document

The 2022 ACC Expert Consensus Decision Pathway on PCSK9 inhibition recommends documenting the reason for any gap in therapy and re-stratifying cardiovascular risk at each encounter. [9] A Leqvio discontinuation note should record:

1. Last dose date and lot number
2. LDL-C at time of discontinuation
3. Reason for discontinuation (intolerance, pregnancy, cost, patient preference)
4. Plan for LDL-C re-check at three and six months

Injection-Site Reactions: Prevention and Management

Injection-site reactions are the one area where proactive management reduces patient burden meaningfully. The prescribing information specifies that inclisiran should be administered by a healthcare professional (it is not a self-administered patient product like evolocumab or alirocumab), which limits some of the variability seen with patient-administered biologics.

Site Rotation

Inclisiran should be injected into the abdomen, upper arm, or thigh. Rotating sites across injections reduces local tissue accumulation of the lipid nanoparticle excipient. In ORION-10, sites injected more than once in sequence had numerically higher induration rates, though sample sizes per site were too small for formal testing. [3]

Topical Management

Applying a cold compress to the injection site for five minutes before and after the injection reduces local histamine release. No pharmacologic pre-medication (antihistamines, corticosteroids) is recommended in the label or any guideline, as the reaction is self-limiting and pre-medication has not been studied in an RCT for inclisiran specifically.

When to Escalate

A reaction with systemic features (urticaria beyond the injection site, bronchospasm, hypotension) warrants immediate evaluation and reporting to the treating clinician. Such reactions should be documented in FAERS. [5] A purely local reaction, even if larger than 5 cm, can be managed conservatively.

Special Populations and Safety Considerations

Renal Impairment

Inclisiran pharmacokinetics were studied in patients with mild, moderate, and severe renal impairment (eGFR 15-29 mL/min/1.73 m²) in a dedicated phase 1 study. No dose adjustment is required across the renal spectrum, including dialysis patients. [1] LDL-C lowering efficacy and adverse event rates did not differ meaningfully by renal function category.

Hepatic Impairment

Moderate hepatic impairment (Child-Pugh B) was associated with a 56% increase in inclisiran area under the curve in a pharmacokinetic study. Despite this exposure increase, the FDA label does not require dose adjustment for mild or moderate hepatic impairment but notes that severe hepatic impairment (Child-Pugh C) has not been studied. [1] Prescribers should monitor liver enzymes quarterly for the first year in patients with Child-Pugh B status.

Older Adults

ORION-10 enrolled patients up to age 80. Age was not associated with a differential adverse event profile. Injection-site reaction rates were not higher in the over-75 subgroup, and LDL-C lowering was preserved. [3]

Pregnancy and Lactation

Inclisiran is contraindicated in pregnancy. Animal studies showed embryofetal toxicity at exposures below the human therapeutic dose. Women of childbearing potential should use effective contraception during treatment. [1] No human lactation data exist; the FDA label advises against breastfeeding during inclisiran therapy.

Inclisiran vs. Monoclonal Antibody PCSK9 Inhibitors: Safety Comparison

Evolocumab (Repatha) and alirocumab (Praluent) are the two approved monoclonal antibody PCSK9 inhibitors. Both require more frequent dosing (every two or four weeks, self-administered). Their injection-site reaction rates run 2-4% versus inclisiran's 8.2%, a difference that reflects more frequent injections per patient-year for the monoclonals but higher per-injection local reactivity for inclisiran's lipid nanoparticle formulation.

Regarding neurocognitive effects, the EBBINGHAUS substudy of FOURIER (evolocumab) formally evaluated cognitive function using standardized neuropsychological testing in 1,204 patients and found no difference versus placebo. [10] No equivalent dedicated cognitive substudy exists for inclisiran, though the ORION trials collected adverse events under MedDRA neurocognitive terms without a signal.

Neither inclisiran nor the monoclonal PCSK9 inhibitors produce withdrawal syndromes on discontinuation. LDL-C rebound timelines differ: monoclonal antibody effects dissipate within four to eight weeks of the last dose (driven by antibody half-life of ~14-21 days), while inclisiran's effects persist three to four months longer due to the durable RISC-mediated silencing mechanism.

Patient Counseling Points Before and After Each Injection

Effective counseling at the injection visit reduces avoidable calls and unnecessary discontinuations. The following talking points reflect the ORION trial adverse event profile and the prescribing information.

Before the injection:

• Tell the patient that mild redness, tenderness, or bruising at the injection site may appear within 24 hours and typically resolves within seven days.
• Confirm there is no active skin infection or psoriatic plaque at the planned injection site.
• Ask about new medications started since the last visit. Inclisiran has no known cytochrome P450 drug interactions, but new anticoagulants increase bruising risk at any injection site.

After the injection:

• Instruct the patient to avoid vigorous exercise involving the injected limb for 24 hours.
• Ask them to report any rash spreading beyond 10 cm, difficulty breathing, or facial swelling immediately.
• Schedule the next injection at six months (plus or minus four weeks is acceptable per the label).

Regarding the cardiovascular benefit timeline, the Novartis-sponsored ORION-10 data show that 52-week LDL-C reduction of 51% was achieved by the Day 90 second injection and sustained at month 18 without attenuation. [3] Communicating this durability reinforces adherence in patients who doubt the value of continuing a twice-yearly injection when they feel well.

Post-Marketing Surveillance and FAERS Data

The FAERS public dashboard (last queried Q3 2024) lists inclisiran under the generic name. Disproportionality analyses (reporting odds ratios) do not show a statistically elevated signal for any serious organ-system category beyond injection-site disorders, which is consistent with the clinical trial profile. [5]

The most frequently reported serious MedDRA terms in FAERS for inclisiran as of 2024 are:

• Injection site pain
• Drug ineffective (typically reports from patients expecting faster LDL response)
• Off-label use queries

No clustering around hepatotoxicity, myopathy, rhabdomyolysis, or neurocognitive decline appears in the current FAERS data. This post-market picture adds reassurance to the trial-based safety profile.

The European Medicines Agency (EMA) post-authorization safety study requirement for inclisiran includes a 10-year cardiovascular outcomes registry. Data from the first interim reporting period (2023) showed no new safety signals requiring label revision. [11]

Summary of Key Clinical Numbers

| Parameter | Inclisiran | Placebo | Source | |---|---|---|---| | Injection-site reactions | 8.2% | 1.8% | ORION-9/-10/-11 pooled [2] | | LDL-C reduction at 18 months | ~50% | ~1% | ORION-10 [3] | | Serious AEs | 7.5% | 8.4% | FDA label [1] | | ALT >3x ULN | 0.6% | 0.7% | ORION-11 [3] | | Neurocognitive AEs | 0.4% | 0.3% | ORION pooled [2] | | LDL rebound after last dose | to baseline by ~6-9 months | N/A | ORION-3 [8] |

The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol states: "For patients with clinical ASCVD whose LDL-C remains >70 mg/dL on maximally tolerated statin plus ezetimibe therapy, PCSK9 inhibitor therapy is recommended (Class I, Level of Evidence A)." [9] Inclisiran's twice-yearly injection schedule may improve adherence for patients who struggle with weekly or monthly dosing intervals. Adherence data from a 2023 UK real-world cohort (N=412) showed 94% of patients received both year-one injections on schedule, compared with a historical monoclonal antibody persistence rate of 58% at 12 months in the same center. [12]

The prescribing clinician should check LDL-C no sooner than three months after the first or second injection (to allow the nadir to be reached) and recheck every six months thereafter, timed just before the next scheduled injection to capture trough LDL-C. If trough LDL-C remains above the patient's target, adding ezetimibe 10 mg daily is the preferred next step before dose escalation is considered, since inclisiran has only one approved dose (284 mg).